Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response

The utility of tumor-derived cell lines is dependent on their ability to recapitulate underlying genomic aberrations and primary tumor biology. Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA). We observed a mutation pattern associated with altered CpGs and APOBEC-family cytosine deaminases similar to mutation signatures derived from somatic alterations in muscle-invasive (MI) primary tumors, highlighting a major mechanism(s) contributing to cancer-associated alterations in the BCa cell line exomes. Non-silent sequence alterations were confirmed in 76 cancer-associated genes, including mutations that likely activate oncogenes TERT and PIK3CA, and alter chromatin-associated proteins (MLL3, ARID1A, CHD6 and KDM6A) and established BCa genes (TP53, RB1, CDKN2A and TSC1). We identified alterations in signaling pathways and proteins with related functions, including the PI3K/mTOR pathway, altered in 60% of lines; BRCA DNA repair, 44%; and SYNE1–SYNE2, 60%. Homozygous deletions of chromosome 9p21 are known to target the cell cycle regulators CDKN2A and CDKN2B. This loci was commonly lost in BCa cell lines and we show the deletions extended to the polyamine enzyme methylthioadenosine (MTA) phosphorylase (MTAP) in 36% of lines, transcription factor DMRTA1 (27%) and antiviral interferon epsilon (IFNE, 19%). Overall, the BCa cell line genomic aberrations were concordant with those found in BCa patient tumors. We used gene expression and copy number data to infer pathway activities for cell lines, then used the inferred pathway activities to build a predictive model of cisplatin response. When applied to platinum-treated patients gathered from TCGA, the model predicted treatment-specific response. Together, these data and analysis represent a valuable community resource to model basic tumor biology and to study the pharmacogenomics of BCa.

[1]  L. Marton,et al.  Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases , 2007, Nature Reviews Drug Discovery.

[2]  Yusuke Nakamura,et al.  Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival , 2014, Clinical Cancer Research.

[3]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[4]  Jae K. Lee,et al.  A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. , 2011, The Lancet. Oncology.

[5]  J. Bertino,et al.  Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity , 2011, Cancer biology & therapy.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[7]  James C. Costello,et al.  TERT promoter mutations and telomerase reactivation in urothelial cancer , 2015, Science.

[8]  Nicholas W. Wood,et al.  A robust model for read count data in exome sequencing experiments and implications for copy number variant calling , 2012, Bioinform..

[9]  Laura Tolosi,et al.  Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. , 2009, The Journal of clinical investigation.

[10]  David Haussler,et al.  Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..

[11]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[12]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[13]  A. Valencia,et al.  The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies , 2015, BMC Genomics.

[14]  Pengyuan Liu,et al.  Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer , 2014, Proceedings of the National Academy of Sciences.

[15]  T. Golub,et al.  Modeling genomic diversity and tumor dependency in malignant melanoma. , 2008, Cancer research.

[16]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[17]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[18]  Jack R. Collins,et al.  AVIA v2.0: annotation, visualization and impact analysis of genomic variants and genes , 2015, Bioinform..

[19]  Zhiming Cai,et al.  Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer , 2014, Clinical Cancer Research.

[20]  Liam O'Connor,et al.  Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer. , 2014, Cancer research.

[21]  Joshua S. Kaminker,et al.  A resource for cell line authentication, annotation and quality control , 2015, Nature.

[22]  T. Michiels,et al.  IFN-ε Is Constitutively Expressed by Cells of the Reproductive Tract and Is Inefficiently Secreted by Fibroblasts and Cell Lines , 2013, PloS one.

[23]  Levi A Garraway,et al.  Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection , 2014, Molecular Cancer Research.

[24]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[25]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[26]  Franziska Michor,et al.  Combination of a Novel Gene Expression Signature with a Clinical Nomogram Improves the Prediction of Survival in High-Risk Bladder Cancer , 2012, Clinical Cancer Research.

[27]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[28]  Mattias Höglund,et al.  Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors , 2008, BMC Medical Genomics.

[29]  Juan Tang,et al.  TNF-alpha promotes Doxorubicin-induced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. , 2005, Biochemical and biophysical research communications.

[30]  H. Zou,et al.  Regularization and variable selection via the elastic net , 2005 .

[31]  J. Rossjohn,et al.  Interferon-ε Protects the Female Reproductive Tract from Viral and Bacterial Infection , 2013, Science.

[32]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[33]  G. Getz,et al.  Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise , 2015, Clinical Cancer Research.

[34]  C. Sander,et al.  Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[36]  Natalia Volfovsky,et al.  AVIA: an interactive web-server for annotation, visualization and impact analysis of genomic variations , 2014, Bioinform..

[37]  Laura M. Heiser,et al.  Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics , 2015, Molecular Cancer Research.

[38]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[39]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[40]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[41]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[42]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[43]  O. Olopade,et al.  Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer. , 1994, Cancer research.

[44]  Qiang Yu,et al.  FOXQ1 regulates epithelial-mesenchymal transition in human cancers. , 2011, Cancer research.

[45]  Konstantinos J. Mavrakis,et al.  Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.

[46]  Y. Xi,et al.  Unraveling the Convoluted Biological Roles of Type I Interferons in Infection and Immunity: A Way Forward for Therapeutics and Vaccine Design , 2014, Front. Immunol..

[47]  Huanming Yang,et al.  SNP detection for massively parallel whole-genome resequencing. , 2009, Genome research.

[48]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[49]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[50]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[51]  E. Messing,et al.  Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. , 2005, The Journal of urology.

[52]  Seungtai Yoon,et al.  A tumour suppressor network relying on the polyamine–hypusine axis , 2012, Nature.

[53]  Jae K. Lee,et al.  Prediction of drug combination chemosensitivity in human bladder cancer , 2007, Molecular Cancer Therapeutics.

[54]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[55]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[56]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[57]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[58]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[59]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.